Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $52.83. Company weekly volatility is calculated as 1.44% and price to cash ratio as 10.92. Merck & Co. Inc. (NYSE:MRK) showed a weekly performance of 1.11%.
Merck & Co. Inc. (NYSE:MRK) won a legal victory over rival Gilead Sciences Inc. on Tuesday when a California jury upheld the validity of two patents that Merck says should entitle it to a portion of the multibillion-dollar sales of Gilead’s hepatitis C drugs.
LATAM Airlines Group S.A. (NYSE:LFL) ended the last trading day at $6.75. Company weekly volatility is calculated as 3.54% and price to cash ratio as 2.66. LATAM Airlines Group S.A. (NYSE:LFL) showed a weekly performance of -0.44%.
LATAM Airlines Group S.A. (NYSE:LFL) and Avianca Holdings SA were both downgraded further into junk territory by Fitch Ratings, which said that the economic slowdown in the region will be an obstacle for them to cut debt.
On 28 March, Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) shares fell -2.67% and was closed at $11.65. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) year to date (YTD) performance is -52.16%.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of RoclatanTM(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. RoclatanTM is a fixed dose combination of Aerie product candidate RhopressaTM (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue).
Bonanza Creek Energy, Inc. (NYSE:BCEI) shares fell -6.71% in last trading session and ended the day at $1.53. BCEI Gross Margin is 73.90% and its has a return on assets of -40.20%. Bonanza Creek Energy, Inc. (NYSE:BCEI) quarterly performance is -74.46%.
Bonanza Creek Energy, Inc. (NYSE:BCEI) announces it has performed a corporate reorganization, which resulted in a total workforce reduction of 26 employees and 17 contractors. The reorganization aligns its employee base and general and administrative cost structure with the current commodity price environment and resulting anticipated activity level.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) caters to the Healthcare space. Its weekly performance is -8.95%. On the last day of trading company shares ended up at $3.46. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) distance from 50-day simple moving average (SMA50) is -95.80%.
Zacks Investment Research upgraded shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) from a hold rating to a buy rating in a research report released on Friday, MarketBeat.Com reports. Zacks Investment Research currently has $4.75 price target on the biopharmaceutical company’s stock.
Leave a Reply